We are live on ! Find out more
ADCT icon

ADC Therapeutics
ADCT

66 hedge funds and large institutions have $177M invested in ADC Therapeutics in 2022 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 9 increasing their positions, 21 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 12

14% more funds holding

Funds holding: 58 → 66 (+8)

2.79% more ownership

Funds ownership: 44.88% → 47.68% (+2.8%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

35% less capital invested

Capital invested by funds: $273M → $177M (-$96.2M)

57% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 21

69% less call options, than puts

Call options by funds: $75K | Put options by funds: $241K

Holders
66
Holders Change
+8
Holders Change %
+13.79%
% of All Funds
1.14%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
20
Increased
9
Reduced
21
Closed
12
Calls
$75K
Puts
$241K
Net Calls
-$166K
Net Calls Change
-$247K

Top Buyers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
+$17.3M
2
BOCH
Blue Owl Capital Holdings
New York
+$5.31M
3
Millennium Management
Millennium Management
New York
+$2.62M
4
PM
Prosight Management
Texas
+$1.79M
5
ECM
ExodusPoint Capital Management
New York
+$1.67M

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$5.58M
2
GGH
GCM Grosvenor Holdings
Illinois
-$4.07M
3
ERSOT
Employees Retirement System of Texas
Texas
-$1.85M
4
Walleye Capital
Walleye Capital
New York
-$1.39M
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$684K
Name Holding Trade Value Shares
Change 		Change in
Stake
Ameriprise
26
Ameriprise
Minnesota
$372K -$20.8K -2,873 -4%
TD Asset Management
27
TD Asset Management
Ontario, Canada
$365K -$127K -17,600 -19%
Renaissance Technologies
28
Renaissance Technologies
New York
$343K -$63.7K -8,800 -11%
ERSOT
29
Employees Retirement System of Texas
Texas
$271K -$1.85M -255,773 -82%
HWAM
30
Hennion & Walsh Asset Management
New Jersey
$248K +$92.9K +12,832 +33%
WP
31
Woodline Partners
California
$229K +$99.4K +13,726 +41%
TI
32
Trexquant Investment
Connecticut
$226K +$340K +46,985 New
Citadel Advisors
33
Citadel Advisors
Florida
$192K +$288K +39,791 New
AA
34
ALPS Advisors
Colorado
$186K -$50.6K -6,992 -15%
Walleye Trading
35
Walleye Trading
New York
$163K +$245K +33,854 New
OCA
36
Octagon Capital Advisors
New York
$145K +$217K +30,000 New
Goldman Sachs
37
Goldman Sachs
New York
$138K +$208K +28,655 New
Rockefeller Capital Management
38
Rockefeller Capital Management
New York
$120K -$645 -89 -0.4%
HF
39
HRT Financial
New York
$108K +$162K +22,422 New
MGIA
40
Moneta Group Investment Advisors
Missouri
$94K +$36 +5 +0%
Susquehanna International Group
41
Susquehanna International Group
Pennsylvania
$86K +$130K +17,922 New
AC
42
Apogem Capital
New York
$84K +$126K +17,405 New
DTL
43
Dynamic Technology Lab
Singapore
$82K +$123K +16,957 New
PP
44
PDT Partners
New York
$76K +$114K +15,768 New
CF
45
CNA Financial
Illinois
$67K -$11.4K -1,570 -10%
CSS
46
Cubist Systematic Strategies
Connecticut
$56K +$83.4K +11,519 New
Man Group
47
Man Group
United Kingdom
$51K +$77.3K +10,673 New
XT
48
XTX Topco
Cayman Islands
$50K +$75.1K +10,368 New
CCG
49
Cypress Capital Group
Florida
$48K – – –
TRCT
50
Tower Research Capital (TRC)
New York
$46K +$63.5K +8,773 +1,253%
1
2
3

ADCT Hedge Fund Activity: Q3 2022 in Review

66 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in ADC Therapeutics (ADCT) for Q3 2022, worth a combined $177M — down 35% from $273M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new ADCT positions and 12 closed out — a net gain of 8 holders — while 9 added to existing stakes and 21 trimmed.

The largest buyer was Deerfield Management, opening a new position worth an estimated $17.3M. The largest seller was T. Rowe Price Associates, cutting an estimated $5.58M.

  • 66 institutional investors held ADC Therapeutics (ADCT) as of Q3 2022, up from 58 in Q2 2022.
  • Funds reported $177M of ADC Therapeutics stock for Q3 2022, down 35% quarter-over-quarter.
  • 20 funds opened new ADC Therapeutics positions in Q3 2022 and 12 closed out, a net change of +8 holders.
  • The largest ADC Therapeutics buyer in Q3 2022 was Deerfield Management, an estimated $17.3M added.
  • The largest ADC Therapeutics seller in Q3 2022 was T. Rowe Price Associates, an estimated $5.58M sold.

Based on aggregated 13F filings for Q3 2022.